CN114853708B - 由羟基查尔酮化合物和黄原酸盐制备4-硫代黄酮化合物的方法 - Google Patents
由羟基查尔酮化合物和黄原酸盐制备4-硫代黄酮化合物的方法 Download PDFInfo
- Publication number
- CN114853708B CN114853708B CN202210574221.4A CN202210574221A CN114853708B CN 114853708 B CN114853708 B CN 114853708B CN 202210574221 A CN202210574221 A CN 202210574221A CN 114853708 B CN114853708 B CN 114853708B
- Authority
- CN
- China
- Prior art keywords
- thioflavone
- compound
- reaction
- hydroxy chalcone
- xanthate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012991 xanthate Substances 0.000 title claims abstract description 14
- BWAGQNPYTNMEJP-UHFFFAOYSA-N 2-phenylchromene-4-thione Chemical class O1C2=CC=CC=C2C(=S)C=C1C1=CC=CC=C1 BWAGQNPYTNMEJP-UHFFFAOYSA-N 0.000 title abstract description 21
- UDOOPSJCRMKSGL-UHFFFAOYSA-N 3-(2-hydroxyphenyl)-1-phenylprop-2-en-1-one Chemical class OC1=CC=CC=C1C=CC(=O)C1=CC=CC=C1 UDOOPSJCRMKSGL-UHFFFAOYSA-N 0.000 title description 2
- 238000004519 manufacturing process Methods 0.000 title description 2
- -1 4-thioflavone compound Chemical class 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 14
- ZOOODBUHSVUZEM-UHFFFAOYSA-N ethoxymethanedithioic acid Chemical compound CCOC(S)=S ZOOODBUHSVUZEM-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000002904 solvent Substances 0.000 claims abstract description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 45
- 238000006243 chemical reaction Methods 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 8
- 239000012046 mixed solvent Substances 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 claims description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 23
- UDOOPSJCRMKSGL-ZHACJKMWSA-N (e)-3-(2-hydroxyphenyl)-1-phenylprop-2-en-1-one Chemical compound OC1=CC=CC=C1\C=C\C(=O)C1=CC=CC=C1 UDOOPSJCRMKSGL-ZHACJKMWSA-N 0.000 description 14
- 238000004440 column chromatography Methods 0.000 description 12
- 238000000926 separation method Methods 0.000 description 12
- 239000007787 solid Substances 0.000 description 11
- RZFBEFUNINJXRQ-UHFFFAOYSA-M sodium ethyl xanthate Chemical compound [Na+].CCOC([S-])=S RZFBEFUNINJXRQ-UHFFFAOYSA-M 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- JCBJVAJGLKENNC-UHFFFAOYSA-M potassium ethyl xanthate Chemical compound [K+].CCOC([S-])=S JCBJVAJGLKENNC-UHFFFAOYSA-M 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 229930003944 flavone Natural products 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229930182496 polymethoxyflavone Natural products 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000005987 sulfurization reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- AHJCTAYXMOPNNT-UHFFFAOYSA-N 3-hydroxy-2-phenylchromene-4-thione Chemical compound O1C2=CC=CC=C2C(=S)C(O)=C1C1=CC=CC=C1 AHJCTAYXMOPNNT-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Chemical class O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 125000005059 halophenyl group Chemical group 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 150000002660 luteolin derivatives Chemical class 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
- 238000001782 photodegradation Methods 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- ZMWBGRXFDPJFGC-UHFFFAOYSA-M potassium;propan-2-yloxymethanedithioate Chemical compound [K+].CC(C)OC([S-])=S ZMWBGRXFDPJFGC-UHFFFAOYSA-M 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一种由羟基查尔酮化合物和黄原酸盐制备4‑硫代黄酮化合物的方法,将羟基查尔酮化合物、黄原酸盐在溶剂中反应,制备硫代黄酮化合物。鉴于4‑硫代黄酮类化合物在药物和环境领域的巨大应用潜力,开发一种简便有效的方法来制备4‑硫代黄酮非常必要,本发明由羟基查尔酮化合物和黄原酸盐制备4‑硫代黄酮化合物,解决了现有技术采用有毒试剂的问题。
Description
技术领域
本发明属于化学合成技术,具体涉及由羟基查尔酮化合物和黄原酸盐制备硫代黄酮化合物的方法。
背景技术
黄酮类化合物广泛存在于植物界,其中很多结构类型的黄酮具有重要的生物活性[(a) Li, S. M.; Pan, M. H.; Lai, C. S.; Lo, C. Y.; Dushenkov, S.; Ho, C. T.Isolation and syntheses of polymethoxyflavones and hydroxylatedpolymethoxyflavones as inhibitors of HL-60 cell lines. Bioorg. Med. Chem.,2007, 15, 3381–3389. (b) Adem, S.; Aslan, A.; Ahmed, I.; Krohn, K.; Guler,C.; Comaklı, V.; Kuzu, M. Inhibitory and activating effects of some flavonoidderivativeson human pyruvate kinase isoenzyme M2. Arch. Pharm. Chem. Life Sci., 2016, 349, 132–136. (c) Spatafora, C.; Tringali, C. Natural-derivedpolyphenols as potential anticancer agents. Anticancer Agents Med. Chem.,2012, 12, 902−918]。4-硫代黄酮作为黄酮的衍生物,其不止在药物化学领域表现出强大的生物学特性如抗癌和抗菌等,在环境监测与保护等领域也凸显很多独特和有价值的功用[(a) Ravishankar, D.; K. A.; Boateng, S. Y.; Green, R. J.; Greco, F.; Osborn,H. M. I. Exploring quercetin and luteolin derivatives as antiangiogenicagents. Eur. J. Med. Chem., 2015, 97, 259−274. (b) Mughala, E. U.; Ayaz, M.;Hussain, Z.; Hasan, A.; Sadiq, A.; Riaz, M.; Malik, A.; Hussain, S.;Choudhary, M. I. Synthesis and antibacterial activity of substitutedflavones, 4-thioflavones and 4-iminoflavones. Bioorg. Med. Chem., 2006, 14,4704–4711. (c)Valente, J. V.; Buntine, M. A.; Lincoln, S. F.; Ward, A. D. UV–Vis and fluorimetric Al3+, Zn2+, Cd2+ and Pb2+ complexation studies of two 3-hydroxyflavones and a 3-hydroxythioflavone. Inorganica Chim. Acta., 2007,360, 3380–3386]。如下所示,化合物1可以产生单线态氧和超氧阴离子,能有效杀死多种细菌和真菌物种,具有较强的抗菌活性,同时化合物1的光降解能力也使其被运用于绿色农药的制备;化合物2具有较强的一氧化氮抑制活性,可用于开发新型神经保护剂;化合物3对Hg2+十分敏感,利用此特点可开发环境中的Hg2+离子选择性信号系统。
现有技术制备4-硫代黄酮的方法主要为:①黄酮化合物与劳森试剂在甲苯中的回流反应,得到4-硫代黄酮;②五硫化二磷作为硫源对黄酮化合物直接进行硫代以合成4-硫代黄酮;③三氯硫磷/水/三乙胺参与的1,3-二酮的环化硫化反应,制备得到4-硫代黄酮。综上所述,目前已报道的4-硫代黄酮的合成方法非常有限,多数方法都基于对预制的黄酮的硫化反应,仅有一例使用了开环的1,3-二酮作为原料,但其所用的硫代试剂三氯硫磷剧毒,非常危险且不易获得。鉴于4-硫代黄酮结构单元的应用价值,开发以易得的链状化合物为原料的此结构单元的合成方法意义重大。
发明内容
鉴于4-硫代黄酮类化合物在药物和环境领域的巨大应用潜力,开发一种简便有效的方法来制备4-硫代黄酮非常必要,本发明由羟基查尔酮化合物和黄原酸盐制备硫代黄酮化合物,解决了现有技术采用有毒试剂的问题。
本发明采用如下技术方案:
一种由羟基查尔酮化合物和黄原酸盐制备硫代黄酮化合物的方法,将羟基查尔酮化合物、黄原酸盐在溶剂中反应,制备硫代黄酮化合物。
本发明中,羟基查尔酮化合物的化学结构式如下:
黄原酸盐的化学结构式如下:
硫代黄酮化合物的化学结构式如下:
。
上述结构式中,R为烷基,比如甲基、乙基、丙基、异丙基等;M为碱金属,比如钾、钠等;R1选自氢、烷基、烷氧基或者卤素;Ar为芳基,比如Ar为苯基、烷基苯基、烷氧基苯基、卤代苯基、萘基或者杂芳基
本发明中,溶剂为水和有机溶剂,或者为有机溶剂;有机溶剂包括二甲亚砜、N, N-二甲基甲酰胺、1, 3-二甲基-2-咪唑啉酮、N-甲基吡咯烷酮等。优选的,水、有机溶剂的摩尔比为(0.01~2)∶1,优选(0.05~1.25)∶1,再优选(0.1~1)∶1,进一步优选(0.25~1)∶1。
本发明中,反应的温度为100~140℃,优选为110~130℃;时间为1~3小时。
本发明中,羟基查尔酮化合物、黄原酸盐的摩尔比为(0.6~2)∶1,优选(1.5~2)∶1。
本发明开发了2-羟基查尔酮和乙基黄原酸钠的反应,以良好到优异的产率合成了一系列4-硫代黄酮化合物。该方法无需过渡金属催化,原料来源简单易得,反应条件温和,可在含水溶剂中进行,较为环境友好,为4-硫代黄酮类化合物的制备提供了一条有效的新途径。
附图说明
图1为4-硫代黄酮3a单晶衍射图。
具体实施方式
黄原酸盐可以由廉价易得的二硫化碳和醇来实现大规模制备,其反应活性较高,本发明通过使用黄原酸盐作为硫源与2-羟基查尔酮反应,实现4-硫代黄酮的制备。本发明所有原料为市售产品或者根据现有方法常规制备,具体制备操作以及测试为常规方法,如无特殊说明,产率为分离产率,反应在空气中进行,溶剂为分析纯直接使用。
实施例一
向反应瓶中加入2-羟基查尔酮(112.1 mg,0.5 mmol)、乙基黄原酸钾(80.2 mg,0.5 mmol)和2.0 mL二甲亚砜(DMSO),在120 ℃下反应2 h;反应结束后进行柱层析分离,得到了棕色固体,经核磁共振氢谱、碳谱、单晶衍射(图1)、高分辨质谱等一系列测试,该化合物的结构被确定为4-硫代黄酮3a,产率为40%。
实施例二
在实施例一制备方法基础上,将二甲亚砜替换为N, N-二甲基甲酰胺、1, 3-二甲基-2-咪唑啉酮、N-甲基吡咯烷酮,其余不变,得到4-硫代黄酮3a的产率如表1;将二甲亚砜替换为1, 4-二氧六环,反应温度为100℃,其余不变,得到4-硫代黄酮3a的产率如表1;将二甲亚砜替换为甲苯,反应温度为110℃,其余不变,得到4-硫代黄酮3a的产率如表1。
在实施例一方法的基础上,调整反应温度,其余不变,反应产率见表2。
实施例三
向反应瓶中加入2-羟基查尔酮(168.2 mg, 0.75 mmol)、乙基黄原酸钾(80.2 mg,0.5 mmol)和2.0 mL混合溶剂(水与二甲亚砜的摩尔比为0.25∶1),在120 ℃下反应2 h;反应结束后进行柱层析分离,得到了棕色固体,产率为47%。
向反应瓶中加入2-羟基查尔酮(224.3 mg,1 mmol)、乙基黄原酸钾(80.2 mg,0.5mmol)和2.0 mL混合溶剂(水与二甲亚砜的摩尔比为0.25∶1),在120 ℃下反应2 h;反应结束后进行柱层析分离,得到了棕色固体,产率为74%。
向反应瓶中加入2-羟基查尔酮(224.3 mg,1 mmol)、乙基黄原酸钾(80.2 mg,0.5mmol)和2.0 mL混合溶剂(水与二甲亚砜的摩尔比为0.25∶1),在120 ℃下反应1 h;反应结束后进行柱层析分离,得到了棕色固体,产率为69%。
向反应瓶中加入2-羟基查尔酮(224.3 mg,1 mmol)、乙基黄原酸钾(80.2 mg,0.5mmol)和2.0 mL混合溶剂(水与二甲亚砜的摩尔比为0.25∶1),在120 ℃下反应3 h;反应结束后进行柱层析分离,得到了棕色固体,产率为74%。
实施例四
向反应瓶中加入2-羟基查尔酮(224.3 mg,1 mmol)、异丙基黄原酸钾(87.2 mg,0.5 mmol)和2.0 mL混合溶剂(水与二甲亚砜的摩尔比为0.25∶1),在120 ℃下反应2 h;反应结束后进行柱层析分离,得到了棕色固体,产率为85%。
向反应瓶中加入2-羟基查尔酮(224.3 mg,1 mmol)、乙基黄原酸钠(72.1 mg,0.5mmol)和2.0 mL混合溶剂(水与二甲亚砜的摩尔比为0.25∶1),在120 ℃下反应2 h;反应结束后进行柱层析分离,得到了棕色固体,产率为98%。
实施例五
向反应瓶中加入2-羟基查尔酮(224.3 mg,1 mmol)、乙基黄原酸钠(72.1 mg,0.5mmol)和2.0 mL二甲亚砜,在120 ℃下反应2 h;反应结束后进行柱层析分离,得到了棕色固体,产率为58%。
向反应瓶中加入2-羟基查尔酮(224.3 mg,1 mmol)、乙基黄原酸钠(72.1 mg,0.5mmol)和2.0 mL水/二甲亚砜(水、DMSO的摩尔比为0.05∶1),在120 ℃下反应2 h;反应结束后进行柱层析分离,得到了棕色固体,产率为69%。
向反应瓶中加入2-羟基查尔酮(224.3 mg,1 mmol)、乙基黄原酸钠(72.1 mg,0.5mmol)和2.0 mL水/二甲亚砜(水、DMSO的摩尔比为1.25∶1),在120 ℃下反应2 h;反应结束后进行柱层析分离,得到了棕色固体,产率为89%。
实施例六
反应条件为:1.0 mmol 2-羟基查尔酮化合物,0.5 mmol乙基黄原酸钠,2.0 mL混合溶剂(水与二甲亚砜的摩尔比为0.75∶1),120 ℃,反应2 h。
向反应瓶中加入2-羟基查尔酮化合物(底物1,1 mmol)、乙基黄原酸钠(底物2c,0.5 mmol)和2.0 mL水/二甲亚砜(水、DMSO的摩尔比为0.75∶1),在120 ℃下反应2 h;反应结束后进行柱层析分离,得到一系列4-硫代黄酮化合物,见表3。
以2-羟基查尔酮和乙基黄原酸钠作为模板底物进行了克级规模的反应,最终在标准反应条件下以90%的产率实现了4-硫代黄酮的制备。
向反应瓶中加入2-羟基查尔酮(13 mmol)、乙基黄原酸钠(6.5 mmol)和26.0 mL水/二甲亚砜(水、DMSO的摩尔比为0.75∶1),在120 ℃下反应2 h;反应结束后,用乙酸乙酯与水萃取反应液(6×25 mL),合并有机相并用无水硫酸钠干燥,减压除去溶剂。粗产物柱层析得到棕色固体,产率90%。
产物的结构表征如下。
1H NMR (400 MHz, CDCl3) δ 8.60 (dd, J = 8.4, 1.6 Hz, 1H), 8.00 –7.98(m, 2H), 7.79 (s, 1H), 7.75 – 7.70 (m, 1H), 7.58 – 7.51 (m, 4H), 7.45 – 7.41(m, 1H).
1H NMR (400 MHz, CDCl3) δ 8.40 (d, J = 0.8 Hz, 1H), 8.00 – 7.97 (m,2H), 7.79 (s, 1H), 7.56 – 7.52 (m, 4H),7.48 – 7.46 (m, 1H), 2.49 (s, 3H).
1H NMR (400 MHz, CDCl3) δ 7.87 – 7.85 (m, 3H), 7.68 (s, 1H), 7.48 –7.42 (m, 3H), 7.40 – 7.38 (m, 1H), 7.24 – 7.22 (m, 1H), 3.84 (s, 3H).
1H NMR (400 MHz, CDCl3) δ 8.46 (d, J = 2.4 Hz, 1H), 7.90 – 7.88 (m,2H), 7.68 (s, 1H), 7.60 – 7.57 (m, 1H), 7.54 – 7.44 (m, 4H).
1H NMR (400 MHz, CDCl3) δ 8.57 (d, J = 2.4 Hz, 1H), 7.85 – 7.83 (m,2H), 7.68 – 7.66 (m, 1H), 7.64 (s, 1H),7.47 – 7.40 (m, 3H), 7.34 (d, J = 8.8Hz, 1H).
1H NMR (400 MHz, CDCl3) δ 8.42 (d, J = 8.8 Hz, 1H), 7.87 – 7.86 (m,2H), 7.58 (s, 1H), 7.49 –7.43 (m, 3H), 6.91 – 6.84 (m, 2H), 3.89 (s, 3H).
1H NMR (400 MHz, CDCl3) δ 8.15 (d, J = 8.0 Hz, 1H), 8.03 (d, J = 6.8Hz, 2H), 7.82 (s, 1H), 7.54–7.52 (m, 3H), 7.33 (t, J = 8.0 Hz, 1H), 7.20 (d,J = 7.6 Hz, 1H), 4.03 (s, 3H).
1H NMR (400 MHz, CDCl3) δ 8.48 (d, J = 8.0 Hz, 1H), 8.07 (d, J = 7.2Hz, 2H), 7.81 (s, 1H), 7.78 (d, J = 7.6 Hz, 1H) 7.59 –7.53 (m, 3H), 7.35 (t,J = 8.0 Hz, 1H).
1H NMR (400 MHz, CDCl3) δ 8.61 (dd, J = 8.4, 1.6 Hz, 1H), 7.72 – 7.67(m, 1H), 7.57 – 7.55 (m, 1H), 7.49 – 7.47 (m, 1H), 7.43 – 7.39 (m, 3H), 7.32– 7.30 (m, 2H), 2.50 (s, 3H).
1H NMR (400 MHz, CDCl3) δ 8.54 (dd, J = 8.4, 1.6 Hz, 1H), 7.71 – 7.70(m, 3H), 7.68 – 7.64 (m, 1H), 7.51 – 7.49 (m, 1H), 7.37 – 7.29 (m, 3H), 2.41(s, 3H).
1H NMR (400 MHz, CDCl3) δ 8.60 (dd, J = 8.0, 1.6 Hz, 1H), 7.78 (s,1H), 7.75 – 7.71 (m, 1H), 7.58 – 7.56 (m, 2H), 7.49 – 7.48 (m, 1H), 7.45 –7.41 (m, 2H), 7.11 – 7.09 (m, 1H), 3.90 (s, 3H).
1H NMR (400 MHz, CDCl3) δ 8.51 (d, J = 8.4 Hz, 1H), 7.91 (s, 1H), 7.80– 7.79 (m, 1H), 7.73 – 7.69 (m, 1H), 7.66 (s, 1H), 7.54 – 7.48 (m, 2H), 7.45– 7.37 (m, 2H).
1H NMR (400 MHz, CDCl3) δ 8.57 – 8.55 (m, 1H), 8.12 – 8.11 (m, 1H),7.89 – 7.87 (m, 1H), 7.75 – 7.71 (m, 1H), 7.70 (s, 1H), 7.68 – 7.66 (m, 1H),7.58 – 7.55 (m, 1H), 7.44 – 7.41 (m, 1H), 7.40 – 7.37 (m, 1H).
1H NMR (400 MHz, CDCl3) δ 8.55 (d, J = 8.4 Hz, 1H), 7.81 – 7.79 (m,2H), 7.70 (s, 1H), 7.68 – 7.64 (m, 1H), 7.50 – 7.48 (m, 1H), 7.38 – 7.34 (m,1H), 7.27 – 7.25 (m, 2H), 2.37 (s, 3H).
1H NMR (400 MHz, CDCl3) δ 8.53 (dd, J = 8.0, 1.2 Hz, 1H), 7.84 – 7.81(m, 2H), 7.65 – 7.61 (m, 2H), 7.46 – 7.44 (m, 1H), 7.36 – 7.32 (m, 1H), 6.94– 6.91 (m, 2H), 3.82 (s, 3H).
1H NMR (400 MHz, CDCl3) δ 8.54 (d, J = 8.0 Hz, 1H), 7.96 – 7.94 (m,2H), 7.74 (s, 1H), 7.67 – 7.59 (m, 5H), 7.51 – 7.49 (m, 1H), 7.44 – 7.42 (m,2H), 7.39 – 7.33 (m, 2H).
1H NMR (400 MHz, CDCl3) δ 8.364 – 8.361 (m, 1H), 7.92 – 7.87 (m, 2H),7.70 (s, 1H), 7.50 – 7.47 (m, 1H), 7.41 – 7.39 (m, 1H), 7.01 – 6.96 (m, 2H),3.87 (s, 3H), 2.45 (s, 3H).
1H NMR (400 MHz, CDCl3) δ 8.51 – 8.50 (m, 1H), 7.88 – 7.86 (m, 2H),7.67 (s, 1H), 7.61–7.58 (m, 1H), 7.46 – 7.44 (m, 1H), 7.00 – 6.98 (m, 2H),3.88 (s, 3H).
1H NMR (400 MHz, CDCl3) δ 8.61 (dd, J = 8.4, 1.2 Hz, 1H), 8.53 (s,1H), 7.98 – 7.95 (m, 3H), 7.91 – 7.87 (m, 2H), 7.76 – 7.72 (m, 1H), 7.63 –7.61 (m, 1H), 7.60 – 7.55 (m, 2H), 7.45 – 7.41 (m, 1H).
1H NMR (400 MHz, CDCl3) δ 8.65 (d, J = 8.0 Hz, 1H), 8.15 – 8.13 (m,1H), 8.00 – 7.98 (m, 1H), 7.92 – 7.91 (m, 1H), 7.79 – 7.77 (m, 1H), 7.71 –7.68 (m, 1H), 7.61 (s, 1H), 7.55 – 7.48 (m, 4H), 7.44 – 7.41 (m, 1H).
1H NMR (400 MHz, CDCl3) δ 8.57 (d, J = 8.0 Hz, 1H), 8.081 – 8.077 (m,1H), 7.71 – 7.65 (m, 1H), 7.61 (s, 1H), 7.52 – 7.49 (m, 2H), 7.46 – 7.44 (m,1H), 7.41 –7.37 (m, 1H).
1H NMR (400 MHz, CDCl3) δ 8.57 (dd, J = 8.0, 1.2 Hz, 1H), 7.71 – 7.66(m, 3H), 7.49 – 7.47 (m, 1H), 7.41 – 7.38 (m, 1H), 7.224 – 7.216 (m, 1H),6.63 – 6.62 (m, 1H).
小结
本发明开发了2-羟基查尔酮和乙基黄原酸钠的反应,以良好到优异的产率合成了一系列4-硫代黄酮化合物。该方法无需过渡金属催化,原料来源简单易得,反应条件温和,可在含水溶剂中进行,较为环境友好,为4-硫代黄酮类化合物的制备提供了一条有效的新途径。
Claims (1)
1.一种由羟基查尔酮化合物和黄原酸盐制备4-硫代黄酮化合物的方法,其特征在于,将羟基查尔酮化合物、黄原酸盐在溶剂中反应,制备硫代黄酮化合物;羟基查尔酮化合物的化学结构式如下:
;
黄原酸盐的化学结构式如下:
;
硫代黄酮化合物的化学结构式如下:
;
R为烷基;M为碱金属;R1选自氢、烷基、烷氧基或者卤素;Ar为芳基;
溶剂为有机溶剂,或者水和有机溶剂的混合溶剂;有机溶剂包括二甲亚砜、N, N-二甲基甲酰胺、1, 3-二甲基-2-咪唑啉酮、N-甲基吡咯烷酮;
水、有机溶剂的摩尔比为(0.01~2)∶1;羟基查尔酮化合物、黄原酸盐的摩尔比为(0.6~2)∶1;
反应的温度为110~140℃,时间为1~3小时。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210574221.4A CN114853708B (zh) | 2022-05-25 | 2022-05-25 | 由羟基查尔酮化合物和黄原酸盐制备4-硫代黄酮化合物的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210574221.4A CN114853708B (zh) | 2022-05-25 | 2022-05-25 | 由羟基查尔酮化合物和黄原酸盐制备4-硫代黄酮化合物的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114853708A CN114853708A (zh) | 2022-08-05 |
CN114853708B true CN114853708B (zh) | 2024-03-19 |
Family
ID=82638579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210574221.4A Active CN114853708B (zh) | 2022-05-25 | 2022-05-25 | 由羟基查尔酮化合物和黄原酸盐制备4-硫代黄酮化合物的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114853708B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190090122A (ko) * | 2018-01-24 | 2019-08-01 | 전남대학교산학협력단 | 호모아이소플라보노이드 및 플라본 유도체의 단일 단계 합성방법 |
CN110078697A (zh) * | 2019-06-21 | 2019-08-02 | 西南大学 | 3-取代黄烷酮化合物的制备方法 |
CN110294730A (zh) * | 2019-07-15 | 2019-10-01 | 浙江大学 | 一种二氟甲基硫化黄酮类化合物及其制备方法 |
CN113559071A (zh) * | 2021-08-18 | 2021-10-29 | 苏州大学 | 一种co靶向递送系统及其构建方法与应用 |
-
2022
- 2022-05-25 CN CN202210574221.4A patent/CN114853708B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190090122A (ko) * | 2018-01-24 | 2019-08-01 | 전남대학교산학협력단 | 호모아이소플라보노이드 및 플라본 유도체의 단일 단계 합성방법 |
CN110078697A (zh) * | 2019-06-21 | 2019-08-02 | 西南大学 | 3-取代黄烷酮化合物的制备方法 |
CN110294730A (zh) * | 2019-07-15 | 2019-10-01 | 浙江大学 | 一种二氟甲基硫化黄酮类化合物及其制备方法 |
CN113559071A (zh) * | 2021-08-18 | 2021-10-29 | 苏州大学 | 一种co靶向递送系统及其构建方法与应用 |
Non-Patent Citations (2)
Title |
---|
7-硫代黄酮衍生物的合成及其抗癌活性评价;黄险峰等;常州大学学报(自然科学版)(第06期);7-13 * |
Singlet and triplet state properties of substituted flavothiones;Gian G. Aloisi et al.;Physical Chemistry Chemical Physics;第5卷(第16期);3464-3469 * |
Also Published As
Publication number | Publication date |
---|---|
CN114853708A (zh) | 2022-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gu et al. | Synthesis and antitumor activity of α-aminophosphonates containing thiazole [5, 4-b] pyridine moiety | |
NZ601567A (en) | Process for production of delta-9-tetrahydrocannabinol | |
IL89119A (en) | Platinum complexes (VI) for the treatment of tumors and pharmaceutical preparations containing them | |
Parmar et al. | An efficient domino reaction in ionic liquid: synthesis and biological evaluation of some pyrano-and thiopyrano-fused heterocycles | |
CN108752243B (zh) | 一种1,4-萘醌类衍生物及其制备方法和应用 | |
Popa et al. | Organoselenium compounds containing pyrazole or phenylthiazole groups: Synthesis, structure, tin (IV) complexes and antiproliferative activity | |
US4983779A (en) | Process for the preparation of vinyl ethers | |
JP2017513863A (ja) | 4,5−ジヒドロ−1h−ピロロ[2,3−f]キノリン−2,7,9−トリカルボン酸およびその二ナトリウム塩の多形形態、それらの調製方法ならびにそれらの使用 | |
CN114853708B (zh) | 由羟基查尔酮化合物和黄原酸盐制备4-硫代黄酮化合物的方法 | |
Hua et al. | Synthesis and X-ray structures of new phosphorus–selenium heterocycles with an E–P (Se)–E′(E, E′= N, S, Se) linkage | |
CN108689901A (zh) | 一种氮杂环丙烯类化合物的合成方法 | |
CN110467585B (zh) | 一种取代苯并噻唑c2羟基烷基化衍生物温和的制备方法 | |
WO2023225916A1 (zh) | 由羟基查尔酮化合物和黄原酸盐制备4-硫代黄酮化合物的方法 | |
CN104356110B (zh) | 一种硫诱导3,6‑芳香杂环不对称取代‑1,2,4,5‑四嗪化合物及其合成方法 | |
Netscher et al. | Tocopherols by hydride reduction of dialkylamino derivatives | |
PT853624E (pt) | Processo para o fabrico de galantamina e respectivos derivados | |
Brayton et al. | A novel heterocyclic atom exchange reaction with Lawesson's reagent: a one-pot synthesis of dithiomaltol | |
CN101089008A (zh) | 虎眼万年青osw-1皂甙的无a、b环的双环类似物、合成方法和用途 | |
Prachumrat et al. | Synthesis, crystal structure, antioxidant, and α-glucosidase inhibitory activities of methoxy-substituted benzohydrazide derivatives | |
Slitikov et al. | Phosphorylation of aminomethylated derivatives of 2, 7-dihydroxynaphthalenes | |
Patel et al. | Novel tocopheryl compounds XXIV. Studies into the nitrosation chemistry of γ-tocopherol: preparation of 5-nitroso-γ-tocopherol via an organomercury derivative of vitamin E | |
CN104910175B (zh) | 一类香豆素衍生物及其制备方法 | |
Rasadkina et al. | 1, 3-Dihydroxynaphthalene in the synthesis of phosphorus-containing macroheterocycles | |
CN103554134B (zh) | 含色酮结构异噁唑类去甲斑蝥素衍生物及其制备方法与应用 | |
EP3551615B1 (en) | Scalable polypropionate lactone stereotetrads |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |